Jazz Pharmaceuticals plc JAZZ
Set alert
232.96 USD +18.52 +8.63%
As of Nov 3, 10:57 AM ET
218.53 Day range 233.74
131.16 52-week range 261.62
- YTD
- +37.03%
- 1 year
- +68.34%
- Open
- 225.37
- Prev close
- 214.44
- Mkt cap
- 15.12B
- Vol
- 488.37K
- Avg vol
- 892.51K
- EPS
- 3.38
- P/E
- 68.92
- Div yield
- 0.00%
More statistics
- Low
- 218.53
- High
- 233.74
- Forward P/E
- 8.51
- Beta
- 0.37
- Short ratio
- 6.86
- Inst. own
- 103.88%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 23, 2027
- 50-d avg
- 231.96
- 200-d avg
- 216.63
- 1y target
- 295.36
1D chart
Signals (9)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | 10:51 AM | 6 minutes ago |
| SMA: Bullish | 10:47 AM | 10 minutes ago |
| SMA: Bearish | 10:45 AM | 12 minutes ago |
| MACD: Sell Signal | 10:30 AM | 27 minutes ago |
| MACD: Buy Signal | 10:19 AM | 38 minutes ago |
| SMA: Bullish | 10:15 AM | 42 minutes ago |
| SMA: Bearish | 10:13 AM | 44 minutes ago |
| SMA: Bullish | 10:07 AM | 50 minutes ago |
| SMA: Bearish | 10:03 AM | 54 minutes ago |
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 295.36 +26.8% upside
Now 232.96
- Target (low)
- 225.00
- Target (mean)
- 295.36
- Target (high)
- 337.00
Ratings (0m) 22 20 buy · 2 hold · 0 sell
- Strong buy7
- Buy13
- Hold2
- Sell0
- Strong sell0
Recommendation trend
- This month 22
- 1 month ago 22
- 2 months ago 20
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -2.38 | -4.72 – 5.81 | 8.13 | -129.2% | 1.21B | +7.7% | 13 |
| Next quarter | 6.56 | 5.16 – 8.78 | 6.64 | -1.3% | 1.24B | +3.8% | 13 |
| Current year | 15.49 | 13.35 – 24.00 | 8.38 | +84.9% | 4.74B | +11.0% | 13 |
| Next year | 25.20 | 13.70 – 31.39 | 15.49 | +62.6% | 5.02B | +5.9% | 13 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 28, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Oct 21, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Oct 8, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Oct 7, 2026 | Truist Securities | Maintained | Buy | Buy |
| Sep 30, 2026 | Citigroup | Initiated | — | Buy |
| Sep 11, 2026 | UBS | Maintained | Buy | Buy |
| Sep 10, 2026 | Barclays | Maintained | Overweight | Overweight |
| Aug 26, 2026 | Deutsche Bank | Maintained | Buy | Buy |
| Aug 26, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Aug 26, 2026 | Truist Securities | Maintained | Buy | Buy |
| Aug 26, 2026 | Needham | Maintained | Buy | Buy |
| Aug 11, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Aug 4, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Aug 4, 2026 | Truist Securities | Maintained | Buy | Buy |
| Aug 4, 2026 | TD Cowen | Maintained | Buy | Buy |
| Aug 4, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Aug 4, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Aug 4, 2026 | Piper Sandler | Maintained | Overweight | Overweight |
| Aug 4, 2026 | Needham | Maintained | Buy | Buy |
| Aug 4, 2026 | Barclays | Maintained | Overweight | Overweight |
| Aug 4, 2026 | Baird | Maintained | Outperform | Outperform |
| Jul 20, 2026 | Needham | Maintained | Buy | Buy |
| Jul 17, 2026 | Canaccord Genuity | Initiated | — | Buy |
| Jul 14, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Jul 14, 2026 | Barclays | Maintained | Overweight | Overweight |
| Jul 9, 2026 | Deutsche Bank | Maintained | Buy | Buy |
| Jul 7, 2026 | Truist Securities | Maintained | Buy | Buy |
| Jun 10, 2026 | B of A Securities | Maintained | Buy | Buy |
| May 27, 2026 | Barclays | Maintained | Overweight | Overweight |
| May 22, 2026 | Bernstein | Initiated | — | Market Perform |
